LeonaBio, Inc.
LONA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$4.76
KIRA · Stoqly’s AI analyst, in plain words
- LeonaBio, Inc. lost $106M in fiscal 2025.
Market cap
$113M
P/E
—
Revenue
—
Net income
−$106M
Free cash flow
—
Operating margin
—
LeonaBio, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$106M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What LeonaBio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- LeonaBio, Inc.
- CIK
- 0001620463
LeonaBio, Inc. · LONA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$54.9M | −$95.6M | −$118M | −$96.9M | −$106M |
| Diluted EPS | −$1.49 | −$2.53 | −$3.09 | −$25.19 | −$24.70 |
| Cash | |||||
| Cash from operations | −$43.1M | −$72.5M | −$101M | −$97.2M | −$45.7M |
| Capital expenditure | $1.6M | $1.1M | $0.3M | $0.0M | — |
| Free cash flow | −$44.7M | −$73.6M | −$101M | −$97.2M | — |
| Share count change | 208.5% | 2.2% | 0.8% | −89.9% | 11.1% |
| Debt and strength | |||||
| Cash and short-term investments | $254M | $200M | $147M | $51.3M | $88.3M |
| Shareholders' equity | $321M | $235M | $130M | $44.8M | $27.8M |
| Current ratio | 28.1x | 9.7x | 5.4x | 4.2x | 1.9x |
| Interest coverage | −21,340.7x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −18.4% | −34.4% | −64.4% | −110.8% | −290.8% |
| Return on tangible equity | −17.1% | −40.7% | −90.4% | −216.2% | −380.0% |
| Altman Z'' | 33.6 | 10.3 | −1.9 | −26.0 | −22.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.1M
5 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
LeonaBio, Inc. · LONA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.76 a share, the company is worth $113M.
Source: SEC EDGAR XBRL filings (CIK 0001620463). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.